Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients

被引:139
作者
Gohh, RY [1 ]
Yango, AF
Morrissey, PE
Monaco, AP
Gautam, A
Sharma, M
McCarthy, ET
Savin, VJ
机构
[1] Brown Univ, Sch Med, Dept Med, Div Renal Dis, Providence, RI 02912 USA
[2] Brown Univ, Sch Med, Dept Surg, Providence, RI 02912 USA
[3] Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI 53226 USA
关键词
focal segmental glomerulosclerosis; kidney transplantation; plasma pheresis;
D O I
10.1111/j.1600-6143.2005.01112.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Recurrent focal segmental glomerulosclerosis (FSGS) following transplantation is ascribed to the presence of a circulating FSGS permeability factor (FSPF). Plasmapheresis (PP) can induce remission of proteinuria in recurrent FSGS. This study addressed the efficacy of pre-transplant PP in decreasing the incidence of recurrence in high-risk patients. Ten patients at high-risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PP treatments in the peri-operative period. Recurrences were identified by proteinuria > 3 g/day and confirmed by biopsy. Seven patients, including all 4 with first grafts and 3 of 6 with prior recurrence, were free of recurrence at follow-up (238-1258 days). Final serum creatinine in 8 patients with functioning kidneys averaged 1.53 mg/dL. FSGS recurred within 3 months in 3 patients, each of whom had lost prior transplants to recurrent FSGS. Two of these progressed to end-stage renal disease (ESRD) and the third has significant renal dysfunction. Based on inclusion criteria, recurrence rates of 60% were expected if no treatment was given. Therefore, PP may decrease the incidence of recurrent FSGS in high-risk patients. Definitive conclusions regarding optimal management can only be drawn from larger, randomized, controlled studies.
引用
收藏
页码:2907 / 2912
页数:6
相关论文
共 34 条
[1]   Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States [J].
Abbott, KC ;
Sawyers, ES ;
Oliver, JD ;
Ko, CW ;
Kirk, AD ;
Welch, PG ;
Peters, TG ;
Agodoa, LY .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (02) :366-373
[2]   Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange [J].
Andresdottir, MB ;
Ajubi, N ;
Croockewit, S ;
Assmann, KJM ;
Hilbrands, LB ;
Wetzels, JFM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (11) :2650-2656
[3]   RECURRENT FOCAL GLOMERULOSCLEROSIS - NATURAL-HISTORY AND RESPONSE TO THERAPY [J].
ARTERO, M ;
BIAVA, C ;
AMEND, W ;
TOMLANOVICH, S ;
VINCENTI, F .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 (04) :375-383
[4]   PLASMAPHERESIS REDUCES PROTEINURIA AND SERUM CAPACITY TO INJURE GLOMERULI IN PATIENTS WITH RECURRENT FOCAL GLOMERULOSCLEROSIS [J].
ARTERO, ML ;
SHARMA, R ;
SAVIN, VJ ;
VINCENTI, F .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (04) :574-581
[5]   THE RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN KIDNEY-TRANSPLANT PATIENTS TREATED WITH CYCLOSPORINE [J].
BANFI, G ;
COLTURI, C ;
MONTAGNINO, G ;
PONTICELLI, C .
TRANSPLANTATION, 1990, 50 (04) :594-596
[6]   Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis [J].
Baum, MA ;
Stablein, DM ;
Panzarino, VM ;
Tejani, A ;
Harmon, WE ;
Alexander, SR .
KIDNEY INTERNATIONAL, 2001, 59 (01) :328-333
[7]   Risk of renal allograft loss from recurrent glomerulonephritis [J].
Briganti, EM ;
Russ, GR ;
McNeil, JJ ;
Atkins, C ;
Chadban, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (02) :103-109
[8]  
Briggs JD, 1999, NEPHROL DIAL TRANSPL, V14, P564
[9]  
Cameron J S, 1994, Curr Opin Nephrol Hypertens, V3, P602, DOI 10.1097/00041552-199411000-00007
[10]  
Candiano G, 2001, J AM SOC NEPHROL, V12, P143, DOI 10.1681/ASN.V121143